PE20010933A1 - Formulaciones de suspension oral de oxcarbazepina - Google Patents
Formulaciones de suspension oral de oxcarbazepinaInfo
- Publication number
- PE20010933A1 PE20010933A1 PE2000001359A PE0013592000A PE20010933A1 PE 20010933 A1 PE20010933 A1 PE 20010933A1 PE 2000001359 A PE2000001359 A PE 2000001359A PE 0013592000 A PE0013592000 A PE 0013592000A PE 20010933 A1 PE20010933 A1 PE 20010933A1
- Authority
- PE
- Peru
- Prior art keywords
- oral suspension
- suspension formulations
- mpa
- composition
- oral
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940101527 oxcarbazepine oral suspension Drugs 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 229940100692 oral suspension Drugs 0.000 abstract 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001816 oxcarbazepine Drugs 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000009974 thixotropic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
SE REFIERE A UNA COMPOSICION EN SUSPENSION ORAL DE OXACARBAZEPINA (10,11-DIHIDRO-10-OXO-5H-DI-BENZ[b,f]AZEPIN-5-CARBOXAMIDA) DE 1% g/ml A 20%g/ml; UNA MEZCLA DE CARBOXIMETILCELULOSA, CELULOSA MICROCRISTALINA, DE 1.25% g/ml A 1.95% g/ml; UN ANTIOXIDANTE COMO ACIDO ASCORBICO (0,75% g/ml A 2% g/ml; QUE SE CARACTERIZA POR SUS PROPIEDADES FISICOQUIMICAS: pH DE 2-4; CUANDO SE AGITA TIENE UNA VISCOSIDAD DE 5 mPa/s A 52 mPa/s. LA COMPOSICION SE PRESENTA EN FORMA DE SUSPENSION TIXOTROPICA ORAL CAPAZ DE FLUIR LIBREMENTE HACIA AFUERA DE UN ORIFICIO CON UN DIAMETRO DE 3mm, A UNA VELOCIDAD DE 0,3ml/s A 4ml/s. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE ATAQUES TONICOS-CLONICOS PRIMARIOS GENERALIZADOS Y ATAQUES PARCIALES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9930058.4A GB9930058D0 (en) | 1999-12-20 | 1999-12-20 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010933A1 true PE20010933A1 (es) | 2001-09-17 |
Family
ID=10866648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001359A PE20010933A1 (es) | 1999-12-20 | 2000-12-18 | Formulaciones de suspension oral de oxcarbazepina |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8119148B2 (es) |
| EP (2) | EP1437127A1 (es) |
| JP (2) | JP4588281B2 (es) |
| KR (2) | KR100496368B1 (es) |
| CN (1) | CN1216594C (es) |
| AR (1) | AR030175A1 (es) |
| AT (1) | ATE269694T1 (es) |
| AU (1) | AU777619B2 (es) |
| BE (2) | BE1013706A5 (es) |
| BR (1) | BR0016524A (es) |
| CA (1) | CA2390029C (es) |
| CO (1) | CO5261608A1 (es) |
| CZ (1) | CZ302737B6 (es) |
| DE (1) | DE60011809T2 (es) |
| DK (1) | DK1239832T3 (es) |
| ES (1) | ES2223641T3 (es) |
| FR (1) | FR2802423B1 (es) |
| GB (1) | GB9930058D0 (es) |
| HU (1) | HU226486B1 (es) |
| IL (2) | IL149498A0 (es) |
| IT (1) | ITMI20002717A1 (es) |
| MX (1) | MXPA02006142A (es) |
| MY (1) | MY126868A (es) |
| NO (1) | NO331990B1 (es) |
| NZ (1) | NZ518755A (es) |
| PE (1) | PE20010933A1 (es) |
| PL (1) | PL201331B1 (es) |
| PT (1) | PT1239832E (es) |
| RU (1) | RU2277912C2 (es) |
| SK (1) | SK287553B6 (es) |
| TR (2) | TR200201459T2 (es) |
| WO (1) | WO2001045671A2 (es) |
| ZA (1) | ZA200204863B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9930058D0 (en) * | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
| DE10224086A1 (de) * | 2002-05-31 | 2003-12-11 | Bayer Ag | Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker |
| GB0221956D0 (en) * | 2002-09-20 | 2002-10-30 | Novartis Ag | Organic compounds |
| KR101018527B1 (ko) | 2002-09-20 | 2011-03-03 | 에프엠씨 코포레이션 | 미정질 셀룰로즈를 함유하는 화장품 조성물 |
| ATE446759T1 (de) | 2003-09-03 | 2009-11-15 | Novartis Pharma Gmbh | Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden |
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| WO2007007182A2 (en) * | 2005-07-08 | 2007-01-18 | Aurobindo Pharma Limited | Solid and liquid dosage forms of an antiepileptic agent |
| WO2007052289A2 (en) | 2005-07-22 | 2007-05-10 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
| US7722898B2 (en) * | 2006-04-26 | 2010-05-25 | Supernus Pharmaceuticals, Inc. | Modified-release preparations containing oxcarbazepine and derivatives thereof |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| KR20080076667A (ko) * | 2007-02-15 | 2008-08-20 | 주식회사 중외제약 | 요변성 약학 조성물 |
| BR112012005254A2 (pt) * | 2009-09-10 | 2016-03-15 | Bial Portela & Ca Sa | formulação de suspensão oral, uso da solução de sorbitol em combinação com goma de xantano, processo para preparar uma formulação de suspensão oral compreendendo acetato de eslicarbazepina |
| CN104288104A (zh) * | 2014-09-24 | 2015-01-21 | 万特制药(海南)有限公司 | 奥卡西平干混悬剂及其制备方法 |
| CN109069480A (zh) | 2015-12-30 | 2018-12-21 | 阿达玛斯医药公司 | 用于治疗与癫痫相关的病症的方法和组合物 |
| CN109010322A (zh) * | 2018-07-13 | 2018-12-18 | 山东达因海洋生物制药股份有限公司 | 一种包含奥卡西平的口腔分散膜剂及其制备方法 |
| CN115487145B (zh) * | 2022-10-10 | 2023-09-01 | 上海奥科达医药科技股份有限公司 | 一种奥卡西平口服混悬液及其制备方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH500196A (de) | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| US4004029A (en) * | 1974-05-13 | 1977-01-18 | The Upjohn Company | Compositions and method for treating epilepsy and convulsions |
| US4431641A (en) * | 1980-10-17 | 1984-02-14 | Ciba-Geigy Corporation | Pharmaceutical compositions having antiepileptic and antineuralgic action |
| RO81639A2 (ro) * | 1981-02-27 | 1983-06-01 | Intreprinderea De Medicamente "Biofarm",Ro | Procedeu de obtinere a unei pulberi suspendabile oxrale de ampicilina |
| CH649080A5 (de) | 1981-04-16 | 1985-04-30 | Ciba Geigy Ag | 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz. |
| US4427681A (en) | 1982-09-16 | 1984-01-24 | Richardson-Vicks, Inc. | Thixotropic compositions easily convertible to pourable liquids |
| JPS60204713A (ja) | 1984-03-30 | 1985-10-16 | Zenyaku Kogyo Kk | 水性懸濁組成物 |
| US4693901A (en) | 1985-12-10 | 1987-09-15 | Cardinal Biological, Ltd. | Shelf stable dairylike products |
| GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
| IL86211A (en) * | 1987-05-04 | 1992-03-29 | Ciba Geigy Ag | Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation |
| IL90245A (en) | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it |
| ES2054089T3 (es) | 1988-11-10 | 1994-08-01 | Ciba Geigy Ag | Formulaciones orales liquidas. |
| GB9102579D0 (en) | 1991-01-24 | 1991-03-27 | Glaxo Group Ltd | Compositions |
| US5272137A (en) | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
| GB9219524D0 (en) * | 1992-09-15 | 1992-10-28 | Smithkline Beecham Plc | Novel composition |
| FR2699077B1 (fr) | 1992-12-16 | 1995-01-13 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes. |
| DE69324504T2 (de) * | 1993-01-19 | 1999-08-26 | Warner-Lambert Co. | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
| FR2702148B1 (fr) | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| FR2702149B1 (fr) | 1993-06-03 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application de la lamotrigine dans le traitement du neuro-sida. |
| FR2702151B1 (fr) | 1993-06-03 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| US5472714A (en) * | 1993-09-08 | 1995-12-05 | Ciba-Geigy Corporation | Double-layered oxcarbazepine tablets |
| US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
| DE4423078B4 (de) * | 1994-07-01 | 2005-01-13 | Awd.Pharma Gmbh & Co. Kg | Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung |
| AU689663B2 (en) | 1994-10-14 | 1998-04-02 | Janssen Pharmaceutica N.V. | Sabeluzole oral suspensions |
| DE4443966A1 (de) * | 1994-12-09 | 1996-06-13 | Basf Ag | Thermoplastische Formmassen |
| PT101732B (pt) | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
| IT1277663B1 (it) | 1995-09-28 | 1997-11-11 | Crinos Industria Farmaco | Sospensioni acquose stabili di mesalazina per uso topico |
| PT101876B (pt) * | 1996-05-27 | 1999-09-30 | Portela & Ca Sa | Novos derivados de 10,11-di-hidro-10-oxo-5h-dibenzo(b,f)azepina-5-carboxamida |
| IT1286496B1 (it) | 1996-11-20 | 1998-07-15 | Leetrim Ltd Dublin | Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria |
| US6037380A (en) * | 1997-04-11 | 2000-03-14 | Fmc Corporation | Ultra-fine microcrystalline cellulose compositions and process |
| US6146876A (en) * | 1999-06-11 | 2000-11-14 | Millennium Pharmaceuticals, Inc. | 22025, a novel human cyclic nucleotide phosphodiesterase |
| GB9930058D0 (en) * | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
-
1999
- 1999-12-20 GB GBGB9930058.4A patent/GB9930058D0/en not_active Ceased
-
2000
- 2000-12-12 CO CO00094330A patent/CO5261608A1/es not_active Application Discontinuation
- 2000-12-13 FR FR0016220A patent/FR2802423B1/fr not_active Expired - Lifetime
- 2000-12-14 BE BE2000/0787A patent/BE1013706A5/fr not_active IP Right Cessation
- 2000-12-15 IT IT2000MI002717A patent/ITMI20002717A1/it unknown
- 2000-12-18 PE PE2000001359A patent/PE20010933A1/es not_active Application Discontinuation
- 2000-12-18 AR ARP000106730A patent/AR030175A1/es not_active Application Discontinuation
- 2000-12-19 KR KR10-2002-7007846A patent/KR100496368B1/ko not_active Expired - Lifetime
- 2000-12-19 DK DK00988803T patent/DK1239832T3/da active
- 2000-12-19 IL IL14949800A patent/IL149498A0/xx unknown
- 2000-12-19 JP JP2001546410A patent/JP4588281B2/ja not_active Expired - Lifetime
- 2000-12-19 TR TR2002/01459T patent/TR200201459T2/xx unknown
- 2000-12-19 SK SK865-2002A patent/SK287553B6/sk not_active IP Right Cessation
- 2000-12-19 KR KR10-2004-7015495A patent/KR20040098034A/ko not_active Ceased
- 2000-12-19 EP EP20040007509 patent/EP1437127A1/en not_active Withdrawn
- 2000-12-19 RU RU2002119210/15A patent/RU2277912C2/ru active
- 2000-12-19 MY MYPI20005952A patent/MY126868A/en unknown
- 2000-12-19 CZ CZ20022138A patent/CZ302737B6/cs not_active IP Right Cessation
- 2000-12-19 PT PT00988803T patent/PT1239832E/pt unknown
- 2000-12-19 CA CA2390029A patent/CA2390029C/en not_active Expired - Lifetime
- 2000-12-19 ES ES00988803T patent/ES2223641T3/es not_active Expired - Lifetime
- 2000-12-19 AU AU25118/01A patent/AU777619B2/en not_active Expired
- 2000-12-19 PL PL355535A patent/PL201331B1/pl unknown
- 2000-12-19 US US10/168,248 patent/US8119148B2/en not_active Expired - Fee Related
- 2000-12-19 NZ NZ518755A patent/NZ518755A/en not_active IP Right Cessation
- 2000-12-19 MX MXPA02006142A patent/MXPA02006142A/es active IP Right Grant
- 2000-12-19 AT AT00988803T patent/ATE269694T1/de active
- 2000-12-19 EP EP00988803A patent/EP1239832B1/en not_active Expired - Lifetime
- 2000-12-19 WO PCT/EP2000/012968 patent/WO2001045671A2/en not_active Ceased
- 2000-12-19 CN CN008173478A patent/CN1216594C/zh not_active Expired - Lifetime
- 2000-12-19 HU HU0203782A patent/HU226486B1/hu unknown
- 2000-12-19 DE DE60011809T patent/DE60011809T2/de not_active Expired - Lifetime
- 2000-12-19 TR TR2004/02419T patent/TR200402419T4/xx unknown
- 2000-12-19 BR BR0016524-7A patent/BR0016524A/pt not_active Application Discontinuation
-
2001
- 2001-11-30 BE BE2001/0779A patent/BE1014502A5/fr not_active IP Right Cessation
-
2002
- 2002-05-06 IL IL149498A patent/IL149498A/en active IP Right Grant
- 2002-06-14 NO NO20022849A patent/NO331990B1/no not_active IP Right Cessation
- 2002-06-28 ZA ZA200204863A patent/ZA200204863B/xx unknown
-
2006
- 2006-08-14 JP JP2006221159A patent/JP2006312651A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010933A1 (es) | Formulaciones de suspension oral de oxcarbazepina | |
| PT806894E (pt) | Nanoparticulas micelares | |
| ECSP034797A (es) | DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA COMO ANTAGONISTAS II MGLUR2 | |
| ATE380541T1 (de) | Herstellung von vitaminemulsionen und konzentrate davon | |
| BRPI0507342A (pt) | sólidos supersaturados estabilizados de fármacos lipofìlicos | |
| BR0011489A (pt) | Composições formadoras de pelìcula compreendendo amidos modificados e iota-carragenano e processos para a fabricação de cápsulas macias usando as mesmas | |
| HRP20080235T3 (hr) | Formulacija vakcine koja sadrži emulziju ulje-u-vodi | |
| NO992068L (no) | Mikroemulsjon og fremgangsmÕte for fremstilling av denne | |
| BR0211028A (pt) | Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto | |
| BR9916447A (pt) | Emulsão despejável contendo água e óleo, e, processos para a preparação de emulsão despejável contendo água e óleo e para intensificar a estabilidade da emulsão despejável de água em óleo | |
| BR0007781A (pt) | Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf | |
| ECSP044974A (es) | Formulación de suspensión oral estabilizada | |
| WO2002066589A3 (en) | Water-in-oil microemulsion for providing cosmetic attributes to fabric softening base composition | |
| EP1095564A3 (en) | Herbicide suspension concentrates | |
| AR018357A1 (es) | Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos | |
| ES2076890B1 (es) | Suplemento de pienso de sal de acido graso desodorizada. | |
| ATE279917T1 (de) | Klare propofolzusammensetzungen | |
| HRP20030002A2 (en) | STABLE GABAPENTIN HAVING pH WITHIN A CONTROLLED RANGE | |
| BR9913066A (pt) | Utilização de pelo menos de um composto apresentando uma viscosidade de alongamento superior ou igual a duas vezes a da água e uma viscosidade de fluxo inferior ou igual a seis vezes a da água | |
| BR0003233A (pt) | Pirazol, uso do composto na preparação de um medicamento e composição | |
| MX2009006023A (es) | Composicion novedosa. | |
| MY136474A (en) | DIBENZO [b,f] AZEPINE DERIVATIVES AND THEIR PREPARATION | |
| PA8542501A1 (es) | Composicion | |
| PE20030046A1 (es) | Composicion farmaceutica con excipiente modificado | |
| PE20011320A1 (es) | Suspension esteroidal estabilizada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |